Tweet
Lancet Microbe
. 2024 Jan 11:S2666-5247(23)00392-0.
doi: 10.1016/S2666-5247(23)00392-0. Online ahead of print. Influenza incidence, lineages, and vaccine effectiveness estimates in Lima, Peru, 2023
Juan Gonzalo Acevedo-Rodriguez 1 , Carlos Zamudio 1 , Noah Kojima 2 , Fiorella Krapp 1 , Pablo Tsukayama 1 , Victor Giancarlo Sal Y Rosas Celi 3 , Dante Baldeon 1 , Carmen Stefany Neciosup-Vera 3 , Carlos Medina 1 , Elsa Gonzalez-Lagos 1 , Laura Castro 2 , Ashley Fowlkes 2 , Eduardo Azziz-Baumgartner 2 , Eduardo Gotuzzo 4 ; PISAAC working group
Collaborators, Affiliations
No abstract available
PubMed Disclaimer
Conflict of interest statement
JGAR has received support from the US CDC. CZ has received support from the US CDC and Pfizer as an international expert for an expert’s symposia. FK has received support from the US CDC, grants or contracts from the Belgian Directorate of Development Cooperation, the Fogarty International Center of the US NIH, Pfizer as an international expert for an expert’s symposia, Abbott as a key opinion leader advisory board member, and Peruvian Multisectoral Committee to combat antimicrobial resistance as an unpaid member. VGSRC has received support from the US CDC. EGL has received support from the US CDC, the Fogarty International Center of the US NIH, the University of Alabama at Birmingham for the Gorgas Advanced Course, Pfizer as an international expert to support an expert's symposia, the Peruvian Ministry of Health as an unpaid expert, and CFAR at the University of Washington Seattle as an unpaid member. All other authors declare no competing interests. This study was supported by the US Centers for Disease Control and Prevention cooperative agreement award GH00266. CZ and EG had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. FK, JGAR, CZ, VGSRC, FM, PT, EGL, and EG conceived and designed the study. EM coordinated laboratory analysis. PT performed genomic sequencing. PA, FG, SA, CM, VN, MG, and RC coordinated data collection and management. CSNV, DB, and VGSRC performed the statistical analysis. All authors wrote and approved the final manuscript. NK, FK, and EGL drafted, edited, and reviewed the manuscript. LC, AF, and EAB interpreted the findings and edited the manuscript. Data will be shared by the corresponding author upon reasonable request for research purposes. We recognise the contributions from several individuals and institutions to this project, including those from Dr Jorge Ponce, Dr Irma Hidalgo, and Mg Luz Nateros (Diris Lima Centro); Dr Roger Hernández and Dr Ana Quintana (Hospital Cayetano Heredia); Dr César Munayco (CDC Peru); Dr Anna Chard and Dr Sofía Arriola (CDC); and Dr Steev Loyola (Universidad Peruana Cayetano Heredia). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.
. 2024 Jan 11:S2666-5247(23)00392-0.
doi: 10.1016/S2666-5247(23)00392-0. Online ahead of print. Influenza incidence, lineages, and vaccine effectiveness estimates in Lima, Peru, 2023
Juan Gonzalo Acevedo-Rodriguez 1 , Carlos Zamudio 1 , Noah Kojima 2 , Fiorella Krapp 1 , Pablo Tsukayama 1 , Victor Giancarlo Sal Y Rosas Celi 3 , Dante Baldeon 1 , Carmen Stefany Neciosup-Vera 3 , Carlos Medina 1 , Elsa Gonzalez-Lagos 1 , Laura Castro 2 , Ashley Fowlkes 2 , Eduardo Azziz-Baumgartner 2 , Eduardo Gotuzzo 4 ; PISAAC working group
Collaborators, Affiliations
- PMID: 38219756
- DOI: 10.1016/S2666-5247(23)00392-0
No abstract available
PubMed Disclaimer
Conflict of interest statement
JGAR has received support from the US CDC. CZ has received support from the US CDC and Pfizer as an international expert for an expert’s symposia. FK has received support from the US CDC, grants or contracts from the Belgian Directorate of Development Cooperation, the Fogarty International Center of the US NIH, Pfizer as an international expert for an expert’s symposia, Abbott as a key opinion leader advisory board member, and Peruvian Multisectoral Committee to combat antimicrobial resistance as an unpaid member. VGSRC has received support from the US CDC. EGL has received support from the US CDC, the Fogarty International Center of the US NIH, the University of Alabama at Birmingham for the Gorgas Advanced Course, Pfizer as an international expert to support an expert's symposia, the Peruvian Ministry of Health as an unpaid expert, and CFAR at the University of Washington Seattle as an unpaid member. All other authors declare no competing interests. This study was supported by the US Centers for Disease Control and Prevention cooperative agreement award GH00266. CZ and EG had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. FK, JGAR, CZ, VGSRC, FM, PT, EGL, and EG conceived and designed the study. EM coordinated laboratory analysis. PT performed genomic sequencing. PA, FG, SA, CM, VN, MG, and RC coordinated data collection and management. CSNV, DB, and VGSRC performed the statistical analysis. All authors wrote and approved the final manuscript. NK, FK, and EGL drafted, edited, and reviewed the manuscript. LC, AF, and EAB interpreted the findings and edited the manuscript. Data will be shared by the corresponding author upon reasonable request for research purposes. We recognise the contributions from several individuals and institutions to this project, including those from Dr Jorge Ponce, Dr Irma Hidalgo, and Mg Luz Nateros (Diris Lima Centro); Dr Roger Hernández and Dr Ana Quintana (Hospital Cayetano Heredia); Dr César Munayco (CDC Peru); Dr Anna Chard and Dr Sofía Arriola (CDC); and Dr Steev Loyola (Universidad Peruana Cayetano Heredia). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.